Hwail Pharmaceutical Co.Ltd - Asset Resilience Ratio
Hwail Pharmaceutical Co.Ltd (061250) has an Asset Resilience Ratio of 8.68% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Hwail Pharmaceutical Co.Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Hwail Pharmaceutical Co.Ltd's Asset Resilience Ratio has changed over time. See 061250 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Hwail Pharmaceutical Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hwail Pharmaceutical Co.Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩18.50 Billion | 8.68% |
| Total Liquid Assets | ₩18.50 Billion | 8.68% |
Asset Resilience Insights
- Limited Liquidity: Hwail Pharmaceutical Co.Ltd maintains only 8.68% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hwail Pharmaceutical Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Hwail Pharmaceutical Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Hwail Pharmaceutical Co.Ltd (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Hwail Pharmaceutical Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 33.51% | ₩72.26 Billion ≈ $48.97 Million |
₩215.61 Billion ≈ $146.12 Million |
-5.11pp |
| 2023-12-31 | 38.63% | ₩71.84 Billion ≈ $48.69 Million |
₩186.00 Billion ≈ $126.05 Million |
-1.97pp |
| 2022-12-31 | 40.60% | ₩75.35 Billion ≈ $51.06 Million |
₩185.60 Billion ≈ $125.78 Million |
-5.35pp |
| 2021-12-31 | 45.94% | ₩89.20 Billion ≈ $60.45 Million |
₩194.15 Billion ≈ $131.57 Million |
+23.73pp |
| 2020-12-31 | 22.21% | ₩37.69 Billion ≈ $25.54 Million |
₩169.68 Billion ≈ $114.99 Million |
-0.60pp |
| 2019-12-31 | 22.81% | ₩31.80 Billion ≈ $21.55 Million |
₩139.40 Billion ≈ $94.47 Million |
+8.72pp |
| 2018-12-31 | 14.09% | ₩17.39 Billion ≈ $11.78 Million |
₩123.41 Billion ≈ $83.63 Million |
-0.61pp |
| 2017-12-31 | 14.70% | ₩18.22 Billion ≈ $12.35 Million |
₩123.90 Billion ≈ $83.97 Million |
+7.00pp |
| 2016-12-31 | 7.70% | ₩9.91 Billion ≈ $6.71 Million |
₩128.62 Billion ≈ $87.16 Million |
+6.29pp |
| 2015-12-31 | 1.42% | ₩1.99 Billion ≈ $1.35 Million |
₩140.27 Billion ≈ $95.06 Million |
-2.61pp |
| 2014-12-31 | 4.03% | ₩4.95 Billion ≈ $3.36 Million |
₩122.92 Billion ≈ $83.30 Million |
+2.44pp |
| 2013-12-31 | 1.58% | ₩1.95 Billion ≈ $1.32 Million |
₩123.02 Billion ≈ $83.37 Million |
-1.66pp |
| 2012-12-31 | 3.24% | ₩3.67 Billion ≈ $2.49 Million |
₩113.14 Billion ≈ $76.67 Million |
-4.67pp |
| 2011-12-31 | 7.91% | ₩7.81 Billion ≈ $5.30 Million |
₩98.73 Billion ≈ $66.91 Million |
-- |
About Hwail Pharmaceutical Co.Ltd
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.